about
Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinChemical and molecular mechanisms of antioxidants: experimental approaches and model systems.Personalized medicine in cardiovascular diseases.Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarinDrug interactions with antiretrovirals and warfarin.Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine.Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients.Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial.VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients.Personalized medicine: a patient-centered paradigm.Evaluation of the biological activity of naturally occurring 5,8-dihydroxycoumarin.Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients.Protective effect of esculetin against oxidative stress-induced cell damage via scavenging reactive oxygen species.Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.Mitochondria-targeted esculetin inhibits PAI-1 levels by modulating STAT3 activation and miR-19b via SIRT3: Role in acute coronary artery syndrome.Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials.Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled Trials.A randomized controlled trial of genotype-based Coumadin initiation.Influence of coumarin and some coumarin derivatives on serum lipid profiles in carbontetrachloride-exposed rats.
P2860
Q28276514-B8C0D1F7-09DA-4A95-9B40-65F76D073E4DQ34081315-6371FD0E-4919-4F35-9820-C15F085CF8EBQ36306729-8214BB1B-61D1-4907-9A44-58BF9B3E69CDQ37160420-0C3B574C-F4FA-4200-A273-5CF7584593EEQ37679935-83020B10-13B8-4C4B-AE3D-1C5977924001Q38094070-5C8E456D-DE99-4BD3-B8F4-FF85B640EDACQ38384338-B2D19005-71B8-4F95-BBEE-404F31B37037Q38673964-E1E3F781-EF9C-48BF-B5C5-6F860D247A14Q39471514-8DBECFE6-88B1-487F-8C9A-53139983C80AQ39622951-0AA42215-F417-4126-ABC4-76C9C35B04E4Q42649214-346AD700-C7A2-471B-B825-98F68D9CDBEFQ43057310-D11500F4-04A2-4EAB-8C69-7FE19CFABE7DQ44769059-1D5E0894-7763-4618-AC5F-12318E73006EQ45945749-F478899B-7AD2-40AF-B5C4-D5198632DC54Q46238853-3B8E18D6-FC35-4D48-842A-013BAD25E7D9Q46292772-D912666B-1C98-4609-91E2-6AC46E305ABFQ47728750-17BCF520-092E-48F1-9E1D-7AFAA838015EQ48220941-B189765D-84EB-4685-BFDD-7F08008C6F1BQ49110792-7DC6B7D2-D21F-4A5E-8BB8-5770214DB0DDQ50978962-37BB21F8-470D-4000-AA34-3416A96B52E8Q51588530-3B62EE04-FD76-43F4-82F5-90E088205A09Q54412231-92C77A7F-148F-4D88-849D-1F1AACFEBD7D
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The pharmacogenetics of coumarin therapy.
@ast
The pharmacogenetics of coumarin therapy.
@en
type
label
The pharmacogenetics of coumarin therapy.
@ast
The pharmacogenetics of coumarin therapy.
@en
prefLabel
The pharmacogenetics of coumarin therapy.
@ast
The pharmacogenetics of coumarin therapy.
@en
P2093
P2860
P356
P1433
P1476
The pharmacogenetics of coumarin therapy
@en
P2093
Brian F Gage
Charles Eby
Howard L McLeod
P2860
P304
P356
10.2217/14622416.6.5.503
P50
P577
2005-07-01T00:00:00Z